The international study coordinated by the Istituto Europeo di Oncologia (IEO) and the Champalimaud Foundation, in Lisbon, is changing the post-surgical standard of care for breast tumours in women with ductal carcinoma in situ and high-risk lesions. The research findings, recently published in the Journal of Clinical Oncology, confirm the effectiveness of low-dose Tamoxifen in preventing recurrences and new tumours in both premenopausal and postmenopausal women. The study was presented at the ASCO Congress in Chicago in the “Best of ASCO” section as a “practice-changing” work.

fchampalimaud.org